The High Court has been asked to weigh in on whether online ads targeting Australian consumers can be the basis for a trade mark registration, in a long-running intellectual property spat between the maker of Mother Energy drinks and Vittoria Coffee over their respective ‘mother’ marks.
The owners of Mother energy drinks and Vittoria Food & Beverage have both lost their challenges to each other’s ‘Motherland’ and ‘Mothersky’ trade marks and are considering taking the long-running stoush to the High Court.
Telecommunications giant Singtel Optus has been barred from promoting various products using the word ‘boost’ until an intellectual property suit brought by Boost Mobile is resolved.
Boost Mobile has sued telecommunications giant Singtel Optus, alleging it “misappropriated” its goodwill by marketing services under a similar product name after Boost chose to move its mobile network to Telstra.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…
The maker of Mother brand energy drinks has won a stay of a judge’s decision to remove one of its trade marks for non-use, but has been hit with indemnity costs in its ongoing intellectual property stoush with rival Cantarella Bros.
The maker of Mother brand energy drinks has filed an appeal challenging a judge’s decision to remove two of its registered ‘Mother’ trade marks for non-use.
Energy Beverages, which makes Mother brand energy drinks, has failed to convince a judge that two of its ‘Mother’ trade marks should not be removed for non-use.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug was wrongly granted.
Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.